Portage Biotech Overview
Latest ROE for Portage Biotech: 5501.63% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow5501.63%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for PRTG is 5501.63%. That is above the Energy sector average of 13.67%. Investors often review this figure alongside Portage Biotech's historical trend and sector peers before judging valuation or financial health.
Against Energy companies, PRTG currently prints 5501.63% for ROE, while the sector average sits near 13.67%. That is roughly 40134.9% above the sector mean. Large gaps often invite a closer look at Portage Biotech's growth, margins, and balance sheet.
Return on Equity shows how effectively Portage Biotech converts resources into returns. At 5501.63%, PRTG may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting PRTG's ROE (5501.63%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Portage Biotech's ROE against similar Energy names. You can also browse sector and industry screens on Stockcircle for a broader set of Energy companies and their key multiples and fundamentals.
